Journal
EXPERT OPINION ON PHARMACOTHERAPY
Volume 12, Issue 2, Pages 269-283Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1517/14656566.2011.533169
Keywords
-
Categories
Funding
- German Jose Carreras Leukemia Foundation [DJCLS H09/01f, H06/04v, H03/01]
- Deutsche Krebshilfe [106642]
- European Commission [LSHC-CT-2004-503216]
Ask authors/readers for more resources
Areas covered: Definition of failure, its causes, the various approaches to the treatment of imatinib failure such as imatinib dose escalation, second-generation tyrosine kinase inhibitors and stem cell transplantation, and monitoring of residual disease are covered in this review. Selected investigational agents and the management of blast crisis are also reviewed. After reading the review the reader will understand how to manage imatinib failure. Expert opinion: Imatinib failure can be managed in most cases by a careful appraisal of its causes and a rational selection of treatment options.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available